United Therapeutics Co. (NASDAQ:UTHR) Shares Bought by Vident Advisory LLC

Vident Advisory LLC raised its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 15.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 12,221 shares of the biotechnology company’s stock after purchasing an additional 1,596 shares during the period. Vident Advisory LLC’s holdings in United Therapeutics were worth $4,312,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in UTHR. Newbridge Financial Services Group Inc. acquired a new stake in shares of United Therapeutics during the 4th quarter valued at approximately $25,000. Dunhill Financial LLC raised its position in shares of United Therapeutics by 100.0% during the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 50 shares in the last quarter. State of Wyoming acquired a new stake in shares of United Therapeutics during the 4th quarter valued at approximately $62,000. Millstone Evans Group LLC acquired a new stake in shares of United Therapeutics during the 4th quarter valued at approximately $67,000. Finally, MassMutual Private Wealth & Trust FSB raised its position in shares of United Therapeutics by 31.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 58 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Trading Up 1.4%

Shares of NASDAQ UTHR opened at $309.57 on Wednesday. United Therapeutics Co. has a one year low of $264.33 and a one year high of $417.82. The firm has a market capitalization of $13.96 billion, a PE ratio of 13.60, a PEG ratio of 0.97 and a beta of 0.58. The business has a 50-day moving average price of $300.00 and a two-hundred day moving average price of $339.52.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, topping analysts’ consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $794.40 million during the quarter, compared to analyst estimates of $726.82 million. During the same period last year, the company posted $6.17 EPS. The business’s quarterly revenue was up 17.2% compared to the same quarter last year. Research analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current year.

Insider Transactions at United Therapeutics

In other news, Director Tommy G. Thompson sold 2,500 shares of the firm’s stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the sale, the director now directly owns 8,480 shares of the company’s stock, valued at $2,703,424. This trade represents a 22.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the firm’s stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $306.18, for a total value of $3,367,980.00. Following the sale, the executive vice president now directly owns 36,781 shares of the company’s stock, valued at $11,261,606.58. This trade represents a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 55,500 shares of company stock valued at $17,054,780 in the last three months. Corporate insiders own 10.30% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on UTHR shares. Wells Fargo & Company reissued an “equal weight” rating and set a $314.00 price target (down from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Morgan Stanley increased their target price on United Therapeutics from $346.00 to $348.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 1st. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, May 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $425.00 target price on shares of United Therapeutics in a research report on Monday, May 5th. Finally, Bank of America raised United Therapeutics from an “underperform” rating to a “neutral” rating and set a $314.00 target price on the stock in a research report on Monday, April 21st. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $392.00.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.